Document:

<PAGE>
                                                                   Exhibit 10.90

                                            ***TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                          UNDER 17 C.F.R. SECTIONS 200.80(b)(4),
                                                            200.83 AND 240.24b-2

                             COLLABORATION AGREEMENT

                                      Effective: July 9, 2001 ("Effective Date")

        EPIMMUNE INC., having a principal place of business at 5820 Nancy Ridge
Drive, San Diego, CA 92121 ("EPMN"), and GENENCOR INTERNATIONAL, INC., having a
principal place of business at 925 Page Mill Road, Palo Alto, CA 94304-1013
("GCOR") (collectively referred to herein as the "Parties") agree as follows:

        WHEREAS, the Parties have entered into that certain License Agreement of
even date herewith (the "License Agreement") and that certain Securities
Purchase Agreement of even date herewith; and

        WHEREAS,  the Parties have entered  into that certain  Interim  Research
Agreement  effective April 2, 2001 (the "Interim  Research  Agreement"),  and in
connection  with the License  Agreement  the Parties wish to extend the research
and development as initiated in said Interim Research Agreement on the terms and
conditions set forth herein;

        NOW THEREFORE, the Parties agree as follows:

                                    ARTICLE I
                                   DEFINITIONS

1.1  "Biological Material" shall mean materials such as epitopes, constructs,
     expression systems, vectors, DNA or protein, polypeptides, cells, strains,
     mice and the like.

1.2  "Invention" shall mean any invention or discovery, patentable or otherwise,
     which arises out of the Program, and which is first conceived and/or
     reduced to practice during the Collaboration Term.

1.3  "Program" shall mean the research and development activities relating to
     the development of Licensed Products conducted by EPMN and GCOR under this
     Agreement during the Collaboration Term. The Program will be conducted
     pursuant to the Work Plan.

1.4  "Project" shall mean the specific projects for each Virus within the
     overall Program.

1.5  "Project Leader" shall mean the person appointed by EPMN ("EPMN Project
     Leader") and GCOR ("GCOR Project Leader") and approved by the Steering
     Committee to lead the technical efforts for a specified Project.

1.6  "Steering Committee" shall have the meaning set forth in Section 3.1.

                                       1.
<PAGE>

1.7  "Work Plan" shall mean the detailed plan relating to the conduct of the
     Program developed and agreed to in writing by the Parties, as may be
     amended by written agreement of the Parties. The Work Plan will include
     such detail as the objectives of the Program, the research and development
     plan, staffing, timelines, deliverables of the Program and the like. The
     Work Plan is set forth on Exhibit A attached hereto and incorporated
     herein.

All other capitalized terms shall have the meaning set forth in the License
Agreement.

                                   ARTICLE II

                     RESEARCH AND DEVELOPMENT COLLABORATION

2.1  Scope of the Collaboration. The Parties hereby undertake to jointly carry
     out the Program in accordance with the Work Plan attached as Exhibit A
     hereto with the purpose of developing Licensed Products for use and sale
     within the Licensed Field. The Parties from time to time as recommended by
     the Steering Committee may adjust the Work Plan by mutual written
     agreement.

2.2  Interim Research Agreement. Upon the Effective Date of this Agreement, the
     Interim Research Agreement shall terminate and the Interim Project (as
     defined in the Interim Research Agreement) will be incorporated into the
     Program as reflected in the Work Plan.

2.3  Performance. Payment of the funding by GCOR in accordance with Sections 4.1
     and 4.2 shall be a condition to EPMN's obligation to perform the work set
     out in the Work Plan, and shall be a basis for termination of this
     Agreement by EPMN under Section 8.2 if such payments are not timely made.
     Adequate and appropriate staffing by EPMN in accordance with Section 4.3
     shall be a condition to GCOR's obligation to make payments pursuant to
     Section 4.2, and shall be a basis for termination of the Agreement by GCOR
     under Section 8.2 if such staffing is not adequately provided. Performance
     of the work to be conducted by EPMN in accordance with Section 2.4 and
     timely delivery of the deliverables set forth for EPMN in the Work Plan and
     Section 2.5 hereof, shall be a condition to GCOR's obligation to make
     payments pursuant to Section 4.2, and shall be a basis for termination of
     this Agreement by GCOR under Section 8.2.

2.4  Performance Obligations. The Collaboration shall be conducted at and/or
     coordinated from the facilities of each Party under the direction and
     supervision of the Steering Committee. Each Party shall use commercially
     reasonable efforts to diligently carry out and perform its tasks and duties
     under the Program within the time periods set out in the Work Plan. As used
     herein "commercially reasonable efforts" means, unless the Parties agree
     otherwise, those efforts consistent with the exercise of prudent
     scientific, clinical and business judgment, as applied to other products of
     similar scientific and commercial potential. Each Party shall be
     responsible for the administrative management and, subject to the funding

                                       2.
<PAGE>

     obligations of GCOR under Section 4.1, fiscal control and all other
     expenses incurred by it for tasks and duties assigned to it in the Program.
     Prior to any extraordinary expense to be incurred by EPMN, the Steering
     Committee shall review the nature and necessity of such extraordinary
     expense and may make a recommendation to GCOR for its payment of such
     extraordinary expense.

2.5  Deliverables. EPMN will use commercially reasonable efforts to deliver to
     GCOR the deliverables to be provided to GCOR in accordance with the Work
     Plan. GCOR will use commercially reasonable efforts to deliver to EPMN the
     deliverables to be provided to EPMN in accordance with the Work Plan

2.6  Interim Reports. The Project Leaders and such members of the Project teams
     as deemed appropriate shall have teleconference calls at least once every
     two weeks. The EPMN Project Leader will provide a bi-monthly report of
     progress towards goals of the applicable Project to the GCOR Project
     Leader, with a copy to the Steering Committee, due promptly after the end
     of the relevant two-month reporting period. Periodically and at least
     quarterly, the Project Leaders shall report progress on their Project to
     the Steering Committee.

2.7  Final Report. Promptly after the expiration or termination of the
     Collaboration Term, EPMN will provide GCOR a final written report detailing
     all information, data and results arising from the Program (the "Final
     Report"). GCOR shall own the Final Report and notwithstanding Article VII
     hereof shall have the right to use and disclose the contents of the Final
     Report for any purpose.

2.8  Disclaimer. NEITHER PARTY GUARANTEES THE OUTCOME OF ANY WORK PERFORMED
     PURSUANT TO THIS AGREEMENT. EXCEPT AS EXPRESSLY SET FORTH IN THIS
     AGREEMENT, THE LICENSE AGREEMENT AND THE SECURITIES PURCHASE AGREEMENT,
     NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY TO THE OTHER PARTY OF
     ANY NATURE, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY
     OF NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

                                   ARTICLE III
                               STEERING COMMITTEE

3.1  Membership. A committee (the "Steering Committee") consisting of three (3)
     members appointed by EPMN and three (3) members appointed by GCOR shall be
     established in order to monitor and coordinate the joint collaboration
     efforts under this Agreement including the Program. The Steering Committee
     members of a Party shall collectively have one (1) vote total on any matter
     within the scope of the Program coming before the Steering Committee. The
     Steering Committee may invite additional non-voting representatives from
     both Parties to participate in meetings as deemed necessary and
     appropriate.

                                       3.
<PAGE>

3.2  Responsibilities. The Steering Committee shall have general responsibility,
     subject to the provisions of Section 3.4 below, for directing the research
     and development efforts under the Program and for monitoring the work done
     under the Program. The Steering Committee shall in good faith discuss
     matters related, but not limited, to:

                -   Goals of the Collaboration;

                -   Setting of priorities and time frames for the performance of
                    certain activities and deliverables outlined in the Work
                    Plan;

                -   Possible changes to, expansion of or abandonment of the Work
                    Plan;

                -   Possible conflicts of interest;

                -   Inclusion of any third parties or any intellectual property
                    rights or know-how belonging to third parties in a Project;

                -   Review any proposed extraordinary expenses by EPMN relating
                    to or necessitated by its performance under the Work Plan
                    and make a recommendation to GCOR regarding payment of such
                    extraordinary expenses;

                -   Determine achievement of R&D-based milestones;

                -   Personnel requirements for each goal or Project within the
                    Program; and

                -   Funding requirements for each goal or Project within the
                    Program subject to the funding obligations set forth in this
                    Agreement.

3.3  Meetings. The Steering Committee shall hold meetings at such times and
     places as shall be determined by a majority of the entire membership of the
     Steering Committee, provided that in no event shall such meetings be held
     less frequently than once every quarter. Such meetings may be held in
     person or by telephone conference, provided that any decision made during a
     telephone conference is evidenced by a confirmed writing signed by one or
     more of the members of the Steering Committee from each Party. The Steering
     Committee shall keep minutes of each of its meeting, which shall include a
     description of all actions approved and any action items to be addressed.

3.4  Votes. Actions to be taken by the Steering Committee pursuant to the terms
     of this Agreement shall only be taken following the unanimous vote of the
     Steering Committee. The Steering Committee shall attempt to have all
     decisions approved by all members of the Steering Committee. If the
     Steering Committee is unable to reach a unanimous decision, such matters
     shall be referred to the management of each Party for consideration and
     action. While the Steering Committee may take actions to coordinate the
     efforts taken by each Party under the Program and to make recommendations
     concerning the matters set forth in Section 3.2, the Steering Committee
     shall not have any authority to enter into any contract or to amend the
     terms and condition of this Agreement or the License Agreement or incur any
     liability on behalf of either Party but shall be required to refer any such
     matters to, and obtain authorization from, the respective management of
     each Party.

                                       4.
<PAGE>

     Notwithstanding the creation of the Steering Committee, each Party shall
     retain the rights, powers and discretion granted to it under this Agreement
     and such Steering Committee shall not be delegated with any such rights,
     powers or discretion unless the Parties expressly agree in writing.

3.5  Expenses. Each Party shall bear all expenses of its representatives related
     to the Steering Committee and the attendance at any meetings of the
     Steering Committee.

                                   ARTICLE IV
                                     FUNDING

4.1  Funding. Subject to the terms and conditions set forth herein, during the
     Collaboration Term GCOR shall fund annually up to [...***...] EPMN full
     time equivalents (FTE) at [...***...] for the work performed under the Work
     Plan. This payment is based on the [...***...] expended by EPMN in support
     of the Program.

4.2  R&D Expense Payments. GCOR agrees to make [...***...] to EPMN within
     [...***...] of the date GCOR receives the last of EPMN's [...***...]
     expended on behalf of the Program during the previous [...***...]. Promptly
     (and in any event within [...***...]), after the Effective Date hereof and
     receipt of EPMN's [...***...] expended on the Interim Research Project,
     GCOR will pay EPMN the balance due for the work performed on the Interim
     Research Project.

4.3  Staffing. Staffing levels will be mutually agreed to by the Parties in
     writing through the operation of the Steering Committee and based on the
     needs of the Program. The overall levels of personnel allocated to the
     Program will be reviewed and adjusted quarterly by the Steering Committee
     to reflect the needs of the Program. There will be a designated Project
     Leader from each Party for each Project within the Program. The EPMN
     Project Leader for each Project may not be changed without the prior
     consent of GCOR, which will not unreasonably be withheld. The Steering
     Committee will review quarterly the EPMN personnel working on the Program.

4.4  GCOR Costs. GCOR will pay [...***...] for work on the Program, [...***...].

4.5  Late Payments. In the event that any payment due hereunder is not made when
     due, the payment shall accrue interest from the date due at the rate of
     [...***...]; provided, however, that in no event shall such rate exceed the
     maximum legal annual interest rate. The payment of such interest shall not
     limit a Party from exercising any other rights it may have as a consequence
     of the lateness of any payment.

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                       5.
<PAGE>

                                    ARTICLE V
                              R&D-BASED MILESTONES

5.1  R&D-Based Milestones. Upon determination by the Steering Committee, based
     on its review of the scientific data and results of the Program, that a
     particular milestone was achieved, GCOR will make certain non-refundable,
     lump sum payments to EPMN ("R&D Milestone Payments"). The technical
     criteria, timelines or other factors affecting payment and the relevant
     payment amounts are provided in Table I.

5.2  Timing of Payment. Promptly, and no later than [...***...] after the
     Steering Committee determines that a milestone has been met, GCOR shall pay
     EPMN the applicable R&D Milestone Payment.

                                     TABLE I

<TABLE>
<CAPTION>
Technical Target for        Time of achievement         Amount of Milestone
each Project                of Target                   Payment to EPMN
--------------------        -------------------         -------------------
<S>                         <C>                         <C>
HBV Project
EpiGene II HBV              [...***...]                 [...***...]
validated for
immunogenicity
--------------------        -------------------         -------------------
HPV Project
EpiGene CTL                 [...***...]                 [...***...]
Cassette for HPV
16/18/45/31/33/58/52
--------------------        -------------------         -------------------
HCV Project
EpiGene CTL                 [...***...]                 [...***...]
Cassette of HCV
conserved
sequences validated
for immunogenicity
--------------------        -------------------         -------------------
</TABLE>

* "Work Plan Date" shall mean the date for achievement of the applicable
milestone as set forth in the Work Plan as of the Effective Date.

                                   ARTICLE VI
                 OWNERSHIP OF RESULTS AND INTELLECTUAL PROPERTY

6.1  EPMN Technology. EPMN Technology shall continue to be owned or Controlled
     by EPMN, subject to the licenses granted to GCOR pursuant to the License
     Agreement.

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                       6.
<PAGE>

6.2  Inventions and Patent Rights. The inventing Party shall own Inventions and
     Patent Rights relating thereto. Subject to the licenses granted to GCOR and
     EPMN pursuant to the License Agreement, EPMN shall own all Sole
     Collaboration Patent Rights and EPMN and GCOR shall jointly own all Joint
     Collaboration Patent Rights. Inventorship shall be determined in accordance
     with US Patent Law. Any disputes regarding inventorship shall be brought to
     the Steering Committee, who acting on advice of counsel will try to resolve
     such disputes in a manner consistent with maintaining the validity of the
     Patent Right. Each Party shall promptly notify the other Party of any
     Inventions made pursuant to this Agreement, such notice to include a copy
     of an invention report or disclosure form.

6.3  Preparation and Prosecution of Sole Collaboration Patent Rights. After
     notice to GCOR, EPMN shall be entitled to apply for patent protection in
     its own name and at its own expense for any Sole Collaboration Patent
     Rights. EPMN shall routinely and at least [...***...] provide GCOR (through
     the Steering Committee) with information on the status of said Sole
     Collaboration Patent Rights including reports on the filing, prosecution
     and issuance of such. EPMN will provide GCOR an opportunity to discuss and
     will consider in good faith GCOR's suggestions regarding major prosecution
     events with respect to the Sole Collaboration Patent Rights. Such major
     prosecution events shall include substantive amendments to claims, response
     to final rejections and notices of allowance, filing decisions in the US as
     well as foreign patent offices, oppositions, revocations, re-examination or
     other substantive prosecution matters with respect to the Sole
     Collaboration Patent Rights. In the event that EPMN desires to abandon any
     patent application or patent included within the Sole Collaboration Patent
     Rights, EPMN shall provide reasonable prior written notice to GCOR of such
     intention to abandon, and at GCOR's request assign or otherwise transfer to
     GCOR all of EPMN's right, title and interest in and to the Sole
     Collaboration Patent Rights designated in such notice and shall execute all
     documents necessary to effect such assignment or transfer.

6.4  Preparation and Prosecution of Joint Collaboration Patent Rights. EPMN and
     GCOR shall jointly agree to apply for patent protection in their joint
     names for any Joint Collaboration Patent Rights. In the event the Parties
     agree to file Joint Collaboration Patent Rights, the Parties will agree
     which Party is in a better position to prepare, file and prosecute such
     Patent Rights. In absence of an agreement, an independent attorney,
     mutually agreeable to the Parties, will file Joint Collaboration Patent
     Rights. GCOR will bear the external expense for preparing, filing and
     prosecuting the Joint Collaboration Patent Rights. In the event that one
     Party desires to abandon any patent application or patent included within
     the Joint Collaboration Patent Rights (including any election by GCOR to
     discontinue payment of expenses with respect to any patent application or
     patent included within the Joint Collaboration Patent Rights), such Party
     shall provide reasonable prior written notice to the other Party of such
     intention to abandon, and at the request of the other Party, assign or
     otherwise transfer to such other Party all of such Party's right, title and
     interest in and to the Joint Collaboration Patent Rights

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                       7.
<PAGE>

     designated in such notice and shall execute all documents necessary to
     effect such assignment or transfer.

6.5  Patent Enforcement. In the event of third party infringement of
     Collaboration Patent Rights, the Parties shall comply with the terms of
     Section 8.2 in the License Agreement.

                                   ARTICLE VII
                                 CONFIDENTIALITY

7.1  Confidentiality. Sections 11.1 and 11.2 of the License Agreement shall
     control the disclosure of any Confidential Information made by either Party
     hereunder.

7.2  Biological Material. Any Biological Material made available to a party
     ("Receiving Party") by the other party ("Delivering Party") is made
     available for research purposes within the Program only and shall not be
     used for any other purpose without the prior written consent of the
     Delivering Party. Biological Material provided hereunder will not be used
     for experiments in which human beings are subjected to the Biological
     Material, nor for research purposes other than the Program, for third
     parties, nor will Biological Material be transferred to any party outside
     the Receiving Party without the prior written consent of the Delivering
     Party. The Receiving Party obtains no rights or license in the transferred
     Biological Material nor may the Receiving Party file any patent
     applications claiming such Biological Material without the Delivering
     Party's prior consent. The Receiving Party will handle such Biological
     Material in compliance with all laws, regulations and guidelines applicable
     to the Biological Material and its use. The Biological Material is
     experimental in nature, and is provided AS IS without any warranties with
     respect to performance or fitness for particular purpose, or to
     completeness and accuracy of information accompanying the Biological
     Material. The Receiving Party acknowledges that the Biological Material is
     provided AS IS and without any representation or warranty, express or
     implied unless otherwise agreed by the Parties.

                                  ARTICLE VIII
                              TERM AND TERMINATION

8.1  Term. This Agreement, unless terminated sooner as provided elsewhere
     herein, shall expire on September 1, 2003, which term can be extended by
     mutual agreement of the Parties.

8.2  Termination Due to Material Breach. If a Party to this Agreement commits a
     material breach of any provision of this Agreement (including but not
     limited to Articles II, IV, VI and VII) and fails to remedy such breach
     within [...***...] with respect to the breach of any payment obligation)
     after written notice thereof from the other Party stating the intent to
     terminate, the Party not in default may, at its option, terminate this
     Agreement by giving written notice to the Party in default.

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                       8.
<PAGE>

8.3  Termination Due to Termination of the License Agreement. If a Party to this
     Agreement terminates the License Agreement as a result of the other Party's
     commission of a material breach thereof and failure to cure same within the
     applicable terms of the License Agreement, the Party so terminating the
     License Agreement shall be permitted to terminate this Agreement.

8.4  Effect of Termination by GCOR. In the event of termination by GCOR pursuant
     to Sections 8.2 or 8.3, GCOR shall pay to EPMN all payments for [...***...]
     actually expended by EPMN as of the effective date of termination but shall
     have no further obligation to make payment for work that was not performed
     as of the effective date of termination. GCOR may at its discretion and
     cost, ask EPMN to continue to work on the Program for no more than
     [...***...] in order to wind down all research and development efforts.
     Upon such termination, EPMN shall promptly provide the Final Report of
     Section 2.7 to GCOR. In the event of such termination, the provisions of
     Section 10.5.3 of the License Agreement shall apply.

8.5  Effect of Termination by EPMN. In the event of termination by EPMN pursuant
     to Section 8.2 or 8.3, GCOR shall pay to EPMN all payments for [...***...]
     actually expended by EPMN as of the effective date of termination. In the
     event of such termination, the provisions of Section 10.5.1 of the License
     Agreement shall apply.

8.6  Survival. Expiration or termination of this Agreement shall not terminate
     any obligation of either Party to the other Party, including any payment
     obligation, that has accrued prior to the date of expiration or
     termination. The provisions contained in Sections 2.7, 6.1, 6.2, 8.4, 8.5,
     8.6 and 8.7 and Articles VII and IX of this Agreement shall survive its
     expiration or earlier termination.

8.7  Remedies. In the event of any breach of any provision of this Agreement, in
     addition to the termination rights set forth herein, each Party shall have
     all other rights and remedies at law or equity to enforce this Agreement.

                                   ARTICLE IX
                                  MISCELLANEOUS

9.1  Force Majeure. Each of the Parties hereto shall be excused from the
     performance of its obligations hereunder (other than payment obligations)
     and shall not be liable for damages to the other in the event that such
     performance is prevented by circumstances beyond its effective control.
     Such excuse from performance shall continue for as long as the condition
     responsible for such excuse continues and for a period of thirty (30) days
     thereafter, provided that if such excuse continues for a period of one
     hundred and eighty (180) days, the Party whose performance is not being
     prevented shall be entitled to terminate this Agreement. For the purpose of
     this Agreement circumstances beyond the effective control of the Party
     which excuse said Party from performance shall include, without limitation,
     acts of God, enactments, regulations or laws of any government, injunctions
     or judgment of any court, war, civil commotion, destruction of facility or
     materials by fire, earthquake,

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                       9.
<PAGE>

     Tsunami, storm or other casualty, plague of epic proportions, famine, labor
     disturbances and failure of public utilities or common carrier.

9.2  Independent Contractors. Nothing in this Agreement is intended or shall be
     deemed to constitute a partnership, agency, employment or joint venture
     relationship between the Parties. All activities by the Parties hereunder
     shall be performed by the Parties as independent parties. Neither Party
     shall incur any debts or make any commitment for or on behalf of the other
     Party except to the extent, if at all, specifically provided herein or
     subsequently agreed upon.

9.3  Assignment. This Agreement shall not be assignable by either Party without
     the prior written consent of the other Party, such consent not to be
     unreasonably withheld or delayed, except a Party may make such an
     assignment without the other Party's consent to Affiliates or to a
     successor to substantially all of the business assets relating to the
     Licensed Field of such Party, whether by merger, sale of stock, sale or
     transfer of assets or other transaction; provided, however, that in the
     event of such transaction, no intellectual property rights of any Affiliate
     or third party that is an acquiring party shall be included in the
     technology licensed hereunder. This Agreement shall be binding upon and
     inure to the benefit of the Parties' successors, legal representatives and
     assigns.

9.4  Amendments of Agreement. This Agreement may be amended or modified or one
     or more provisions hereof waived only by a written instrument signed by
     both Parties.

9.5  Severability. In the event that any one or more of the provisions of this
     Agreement should for any reason be held by any court or authority having
     jurisdiction over this Agreement and the Parties to be invalid, illegal or
     unenforceable, such provisions shall be deleted in such jurisdiction;
     elsewhere this Agreement shall not be affected.

9.6  Article Headings. The section headings contained in this Agreement are for
     convenience only and are to be of no force or effect in construing and
     interpreting this Agreement.

9.7  Notices. Any notice, report, request, approval, payment, consent or other
     communication required or permitted to be given under this Agreement shall
     be in writing and shall for all purposes be deemed to be fully given and
     received, if delivered in person or sent by registered mail, postage
     prepaid or by facsimile transmission to the respective parties at the
     following addresses:

                    If to EPMN:    EPIMMUNE INC.
                                   5820 Nancy Ridge Drive
                                   San Diego, CA 92121
                                   Attention:  Chief Executive Officer
                                   Fax No: 858-860-2600

                                      10.
<PAGE>

                    If to GCOR:    GENENCOR INTERNATIONAL, INC.
                                   925 Page Mill Road
                                   Palo Alto, CA 94304
                                   Attention:  General Counsel
                                   Fax No: 650-845-6507

     Either party may change its address for the purpose of this Agreement by
     giving the other Party written notice of its new address.

9.8  Non-Waiver For Failure To Enforce Compliance. The express or implied waiver
     by either Party of a breach of any provision of this Agreement shall not
     constitute a continuing waiver of other breaches of the same or other
     provisions of this Agreement.

9.9  Applicable Law. This Agreement shall be construed and interpreted in
     accordance with the laws of the State of California without regard to
     conflict of law provisions.

9.10 Counterparts. This Agreement may be executed in one or more counterparts,
     each of which is an original but all of which, taken together, shall
     constitute one and the same instrument.

    AS WITNESS the hands of authorized signatories for the Parties on the date
first mentioned above.

EPIMMUNE INC.

By:   /s/ Robert J. De Vaere
      ---------------------------------
      Robert J. De Vaere
      Vice President, Finance and
      Chief Financial Officer

GENENCOR INTERNATIONAL, INC.

By:   /s/ Debby Jo Blank
      ---------------------------------
          Debby Jo Blank

Title: CBO
      ---------------------------------

                                      11.
<PAGE>

                                   APPENDIX A

                                    WORK PLAN

[...***...]

                                               *CONFIDENTIAL TREATMENT REQUESTED<PAGE>

                                                                   EXHIBIT 10.91
                                            ***TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                          UNDER 17 C.F.R. SECTIONS 200.80(b)(4),
                                                            200.83 AND 240.24b-2

                                  EPIMMUNE INC.

                                   SECURITIES
                               PURCHASE AGREEMENT

                                  JULY 9, 2001

<PAGE>

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                                        PAGE
<S>                                                                                                     <C>
1.  AUTHORIZATION OF SALE OF THE SECURITIES.........................................................     1

2.  AGREEMENT TO SELL AND PURCHASE THE SECURITIES...................................................     1

3.  CLOSING AND DELIVERY............................................................................     2

    3.1         Closing.............................................................................     2

    3.2         Milestone Closing...................................................................     2

    3.3         Delivery............................................................................     2

4.  REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY........................................     3

    4.1         Organization and Good Standing......................................................     3

    4.2         Corporate Power; Authorization......................................................     3

    4.3         Valid Issuance......................................................................     3

    4.4         SEC Documents; Financial Statements.................................................     4

    4.5         Intellectual Property...............................................................     4

    4.6         Capitalization......................................................................     4

    4.7         Litigation..........................................................................     4

    4.8         Governmental Consents...............................................................     5

    4.9         No Material Adverse Change..........................................................     5

    4.10        Securities Violations...............................................................     5

    4.11        Nasdaq..............................................................................     5

    4.12        Offering Valid......................................................................     5

5.  REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE PURCHASER......................................     5

6.  SURVIVAL OF REPRESENTATIONS, WARRANTIES AND AGREEMENTS, DISCLAIMER, INDEMNIFICATION.............     6

    6.1         Survival............................................................................     6

    6.2         Disclaimer..........................................................................     7

    6.3         Indemnification by the Company......................................................     7

    6.4         Indemnification by the Purchaser....................................................     7

    6.5         Limitation of Liability.............................................................     7

7.  CONDITIONS TO COMPANY'S OBLIGATIONS AT CLOSING..................................................     7

    7.1         Closing.............................................................................     7

    7.2         Milestone Closing...................................................................     8

8.  CONDITIONS TO PURCHASERS' OBLIGATIONS AT CLOSING................................................     8
</TABLE>

                                       i.
<PAGE>

                                TABLE OF CONTENTS
                                   (CONTINUED)

<TABLE>
<CAPTION>
                                                                                                       PAGE
<S>                                                                                                    <C>
    8.1         Closing.............................................................................     8

    8.2         Milestone Closing...................................................................     8

9.  RESTRICTIONS ON TRANSFER; REGISTRATION RIGHTS...................................................     8

    9.1         Certain Definitions.................................................................     8

    9.2         Restrictions on Transfer............................................................     9

    9.3         Registration Procedures.............................................................    10

    9.4         Expenses of Registration............................................................    11

    9.5         Termination of Registration Rights..................................................    11

    9.6         Furnishing Information..............................................................    11

    9.7         Indemnification.....................................................................    12

    9.8         "Market Stand-Off" Agreement........................................................    14

10. RIGHT OF FIRST REFUSAL..........................................................................    14

    10.1        Subsequent Offerings................................................................    14

    10.2        Exercise of Right of First Refusal..................................................    14

    10.3        Issuance of Equity Securities to Other Persons......................................    15

    10.4        Termination of Right of First Refusal...............................................    15

    10.5        No Transfer of Right of First Refusal...............................................    15

    10.6        Excluded Securities.................................................................    15

    10.7        Condition to the Purchaser's Right of First Refusal.................................    16

11. ADDITIONAL COVENANTS............................................................................    16

    11.1        Restricted Transactions.............................................................    16

    11.2        Standstill..........................................................................    16

12. BROKER'S FEE....................................................................................    17

13. NOTICES.........................................................................................    17

14. MISCELLANEOUS...................................................................................    18

    14.1        Waivers and Amendments..............................................................    18

    14.2        Headings............................................................................    18

    14.3        Severability........................................................................    18

    14.4        Governing Law.......................................................................    19

    14.5        Counterparts........................................................................    19
</TABLE>

                                       ii.
<PAGE>

                                TABLE OF CONTENTS
                                   (CONTINUED)

<TABLE>
<CAPTION>
                                                                                                       PAGE
<S>                                                                                                    <C>
    14.6        Successors and Assigns..............................................................    19

    14.7        Entire Agreement....................................................................    19

    14.8        Payment of Fees and Expenses........................................................    19
</TABLE>

                                      iii.
<PAGE>

                                            ***TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                          UNDER 17 C.F.R. SECTIONS 200.80(b)(4),
                                                            200.83 AND 240.24b-2

                          SECURITIES PURCHASE AGREEMENT

       THIS SECURITIES PURCHASE AGREEMENT ("AGREEMENT") is made as of July 9,
2001 (the "EFFECTIVE DATE"), by and between EPIMMUNE INC., a Delaware
corporation with its principal place of business at 5820 Nancy Ridge Drive,
Suite 100, San Diego, California 92121 (the "COMPANY"), and GENENCOR
INTERNATIONAL, INC., a Delaware corporation with its principal place of business
at 925 Page Mill Road, Palo Alto, California (the "PURCHASER").

       WHEREAS, the Company and the Purchaser have entered into that certain
License Agreement of even date herewith (the "LICENSE AGREEMENT") and that
certain Collaboration Agreement of even date herewith (the "COLLABORATION
AGREEMENT"); and

       WHEREAS, in connection with the License Agreement and Collaboration
Agreement, the Company wishes to sell to the Purchaser, and Purchaser wishes to
purchase from the Company, shares of the Company's Common Stock, par value $0.01
per share (the "COMMON STOCK") on the terms and subject to the conditions set
forth in this Agreement.

                                    AGREEMENT

       In consideration of the mutual covenants contained in this Agreement, and
for other good and valuable consideration, the receipt of which is hereby
acknowledged, the Company and the Purchaser hereby agree as follows:

       1. AUTHORIZATION OF SALE OF THE SECURITIES. Subject to the terms and
conditions of this Agreement, the Company has authorized the sale and issuance
of (a) one million one hundred fifty-four thousand seven hundred ninety-seven
(1,154,797) shares of Common Stock (the "SHARES") at the Closing (as defined
below) and (b) that number of shares of Common Stock equal to the lesser of (i)
[...***...] (as adjusted for any stock dividends, combinations, splits,
recapitalizations or similar transactions) or (ii) the maximum number of shares
of Common Stock the Purchaser could acquire such that its beneficial ownership
of any securities or instruments convertible into or exchangeable or exercisable
for securities of the Company does not [...***...] of the total number of shares
of the Common Stock outstanding immediately prior to such issuance (the
"MILESTONE SHARES") at the Milestone Closing (as defined below). The Shares and
the Milestone Shares shall collectively be referred to herein as the
"SECURITIES."

       2. AGREEMENT TO SELL AND PURCHASE THE SECURITIES.

              2.1 At the Closing, the Company will sell to the Purchaser, and
the Purchaser will purchase from the Company, the Shares at a per share purchase
price equal to [...***...] (the "PRICE PER SHARE"), representing [...***...] of
the Closing Value (as defined below), for a total purchase price of [...***...]
(the "TOTAL PURCHASE PRICE"). The term "CLOSING VALUE" shall mean [...***...].

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                       1.
<PAGE>

              2.2 At the Milestone Closing, the Company will sell to the
Purchaser, and the Purchaser will purchase from the Company, the Milestone
Shares at a per share purchase price equal to the [...***...] (the "MILESTONE
PURCHASE PRICE").

       3. CLOSING AND DELIVERY.

              3.1 CLOSING. The closing of the purchase and sale of the Shares
pursuant to this Agreement (the "CLOSING") shall be held at the offices of
Cooley Godward LLP, 4365 Executive Drive, Suite 1100, San Diego, California
92121 on the Effective Date, or on such other date and place as may be agreed to
by the Company and the Purchaser (the "CLOSING DATE"). At or prior to the
Closing, the Purchaser and the Company shall execute any related agreements or
other documents required to be executed hereunder, dated as of the Closing Date.

              3.2 MILESTONE CLOSING. The closing of the purchase and sale of the
Milestone Shares pursuant to this Agreement (the "MILESTONE CLOSING") shall be
held on the fifth (5th) business day immediately following the occurrence of a
Milestone Trigger (the "MILESTONE CLOSING DATE"). For purposes of this
Agreement, a "MILESTONE TRIGGER" shall be deemed to have occurred if: (i) the
Purchaser shall have delivered to the Company a written notice of its desire to
purchase the Milestone Shares within the period commencing with the date of the
filing of an Investigational New Drug Application covering a Licensed Product
(as defined in the License Agreement), and ending at 5:00 p.m. Pacific Time on
the thirtieth (30) day following such filing (the "FIRST PERIOD") or (ii) the
Purchaser shall have delivered to the Company a written notice of its desire to
purchase the Milestone Shares within the period commencing with the delivery of
a Company Request (as defined below) to the Purchaser by the Company and ending
at 5:00 p.m. Pacific Time on the fifth (5) business day following such delivery
(the "SECOND PERIOD"). In the event the [...***...] of the Common Stock, as
reported by the Nasdaq National Market, over any [...***...] period exceeds
[...***...] multiplied by an amount equal to [...***...] of the Closing Value
(as adjusted for any stock dividends, combinations, splits, recapitalizations or
similar transactions), then the Company shall have the right to request that the
Purchaser purchase the Milestone Shares by delivering a written request to the
Purchaser (the "COMPANY REQUEST").

              3.3 DELIVERY.

                     (a) At the Closing, the Company shall deliver to the
Purchaser the stock certificates registered in the name of the Purchaser, and/or
in such nominee name(s) as designated in writing by the Purchaser, representing
the Shares against payment of the Total Purchase Price.

                     (b) At the Milestone Closing, the Company shall deliver to
the Purchaser stock certificates registered in the name of the Purchaser, and/or
in such nominee name(s) as designated by the Purchaser in writing, representing
the Milestone Shares against payment of the Milestone Purchase Price.
Notwithstanding anything to the contrary in this Agreement, the Company shall
not be obligated to issue to the Purchaser any of the Milestone Shares, if such
Milestone Shares have not been purchased pursuant to this Agreement prior to the
earliest of: (i) the expiration of the First Period, (ii) the expiration of the
Second Period or (iii) 5:00 p.m. Pacific Time on the [...***...] of the
Effective Date.

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                       2.
<PAGE>

       4. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY.

       Except as set forth on the Schedule of Exceptions attached hereto as
Exhibit A, the Company hereby represents and warrants as of the date hereof to,
and covenants with, the Purchaser as follows:

              4.1 ORGANIZATION AND GOOD STANDING. The Company has been duly
incorporated and is validly existing as a corporation in good standing under the
laws of the State of Delaware, has full corporate power and authority to own or
lease its properties and conduct its business as presently conducted (as defined
below), and is duly qualified as a foreign corporation and in good standing in
all jurisdictions in which the character of the property owned or leased or the
nature of the business transacted by it makes qualification necessary, except
where the failure to be so qualified would not have a material adverse effect on
the business, properties, financial condition or results of operations of the
Company.

              4.2 CORPORATE POWER; AUTHORIZATION. The Company has all requisite
corporate power, and has taken all requisite corporate action, to execute and
deliver this Agreement, sell and issue the Securities and carry out and perform
all of its obligations under this Agreement. This Agreement constitutes a legal,
valid and binding obligation of the Company, enforceable in accordance with its
terms, except (i) as limited by applicable bankruptcy, insolvency,
reorganization, moratorium or similar laws relating to or affecting the
enforcement of creditors' rights generally, (ii) as limited by equitable
principles generally, including any specific performance, and (iii) to the
extent that the enforceability of those provisions of Section 9.7 relating to
indemnity or contribution may be limited by applicable laws. The execution and
delivery of this Agreement does not as of the Effective Date, and the
performance of this Agreement and the compliance with the provisions hereof and
the issuance, sale and delivery of the Securities by the Company will not at the
date of such performance and compliance, conflict with, or result in a breach or
violation of: (x) the terms, conditions or provisions of, or constitute a
default under, require the approval of its stockholders under, or result in the
creation or imposition of any lien pursuant to the terms of, the Certificate of
Incorporation or Bylaws of the Company; or (y) any statute, law, rule or
regulation (including without limitation, the rules and regulations applicable
to the Nasdaq Stock Market and applicable securities laws) applicable to the
Company or any state or federal order, judgment or decree applicable to the
Company or any indenture, mortgage, lease or other material agreement or
instrument to which the Company or any of its properties is subject, where such
conflict, breach or violation would have a material adverse effect on the
Company.

              4.3 VALID ISSUANCE. The Securities, when issued and paid for in
compliance with the provisions of this Agreement, will be validly issued, fully
paid and nonassessable and will not be issued in violation of any preemptive
right.

              4.4 SEC DOCUMENTS; FINANCIAL STATEMENTS. The Company has filed in
a timely manner all documents that the Company was required to file with the
United States Securities and Exchange Commission (the "SEC") under Sections 13,
14(a) and 15(d) of the Securities Exchange Act of 1934, as amended (the
"EXCHANGE ACT"), during the twelve (12) months preceding the Effective Date. As
of their respective filing dates (or, if amended, when amended), all documents
filed by the Company with the SEC (the "SEC DOCUMENTS") complied

                                       3.
<PAGE>

in all material respects with the requirements of the Exchange Act. None of the
SEC Documents as of their respective dates contained any untrue statement of
material fact or omitted to state a material fact required (under the federal
securities laws in connection with the sale of the Securities) to be stated
therein or necessary to make the statements made therein, in light of the
circumstances under which they were made, not misleading. The financial
statements of the Company included in the SEC Documents (the "FINANCIAL
STATEMENTS") comply as to form and substance in all material respects with
applicable accounting requirements and with the published rules and regulations
of the SEC with respect thereto. The Financial Statements have been prepared in
accordance with generally accepted accounting principles consistently applied
and fairly present the financial position of the Company at the dates thereof
and the results of its operations and cash flows for the periods then ended
(subject, in the case of unaudited statements, to normal, recurring
adjustments).

              4.5 INTELLECTUAL PROPERTY. The Company owns or possesses adequate
rights to use all material patents, patent rights, inventions, trade secrets and
know-how that are necessary for the conduct of its business as presently
conducted and as described in the SEC Documents. Except as set forth in the SEC
Documents, the Company has not received any written notice of, nor has any
knowledge of, any infringement of or conflict with asserted rights of others
with respect to any patent, patent right, invention, trade secret or know-how
that, individually or in the aggregate, if the subject of an unfavorable
decision, ruling or finding, would have a material adverse effect on the
business, properties, financial condition or results or operations of the
Company.

              4.6 CAPITALIZATION. The capitalization of the Company is described
in the Company's SEC Documents. The Company has not issued any capital stock
since March 31, 2001 other than pursuant to employee benefit plans disclosed in
the Company's SEC Documents. The outstanding shares of capital stock of the
Company have been duly and validly issued and are fully paid and nonassessable
and were not issued in violation of any preemptive rights. Except as set forth
in or contemplated by the Company's SEC Documents or as otherwise described in
this Agreement, there are no outstanding rights (including, without limitation,
preemptive rights), warrants or options to acquire, or instruments convertible
into or exchangeable for, any unissued shares of capital stock or other equity
interest in the Company, or any contract, commitment, agreement, understanding
or arrangement of any kind to which the Company is a party and relating to the
issuance or sale of any capital stock of the Company, any such convertible or
exchangeable securities or any such rights, warrants or options.

              4.7 LITIGATION. There is no pending or, to the Company's
knowledge, threatened, action, suit or other proceeding to which the Company is
a party or to which its property or assets are subject that is not disclosed in
the SEC Documents that is required to be so disclosed.

              4.8 GOVERNMENTAL CONSENTS. No consent, approval, order or
authorization of, or registration, qualification, designation, declaration or
filing with, any federal, state, or local governmental authority on the part of
the Company is required in connection with the consummation of the transactions
contemplated by this Agreement except for compliance with the securities and
blue sky laws in the states and other jurisdictions in which Securities are
offered and/or sold, which compliance will be effected in accordance with such
laws.

                                       4.
<PAGE>

              4.9 NO MATERIAL ADVERSE CHANGE. Except as otherwise disclosed
herein, since March 31, 2001, there have not been any changes in the assets,
liabilities, financial condition or operations of the Company from that
reflected in the Company's Form 10-Q for the period ended March 31, 2001 except
changes in the ordinary course of business or which have not been, either
individually or in the aggregate, materially adverse.

              4.10 SECURITIES VIOLATIONS. The Company represents and warrants
that none of its directors or officers is or has within the last five years,
been the subject of, or a defendant in: (i) an enforcement action or prosecution
(or settlement in lieu thereof) brought by a governmental authority relating to
a violation of securities, tax, fiduciary or criminal laws, or (ii) a civil
action (or settlement in lieu thereof) brought by shareholders or investors in a
common investment vehicle for violation of duties owed to the shareholders or
investors.

              4.11 NASDAQ. The Company's Common Stock is listed on The Nasdaq
National Market and the Company shall use its commercially reasonable efforts to
maintain such listing.

              4.12 OFFERING VALID. Assuming the accuracy of the representations
and warranties of the Purchaser contained in Section 5.1 hereof, the offer and
issuance of the Securities will be exempt from the registration requirements of
the Securities Act of 1933, as amended (the "SECURITIES ACT"), and will have
been registered or qualified (or are exempt from registration and qualification)
under the registration, permit or qualification requirements of all applicable
state securities laws. Neither the Company nor any agent on its behalf has
solicited or will solicit any offers to sell or has offered to sell or will
offer to sell all or any part of the Securities to any person or persons so as
to bring the sale of such Securities by the Company within the registration
provisions of the Securities Act or any state securities laws.

       5. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE PURCHASER.

              5.1 The Purchaser represents and warrants to and covenants with
the Company that:

                     (a) The Purchaser, taking into account the personnel and
resources it can practically bring to bear on the purchase of the Securities
contemplated hereby, either alone or together with the advice of the Purchaser's
representative, is knowledgeable, sophisticated and experienced in making, and
is qualified to make, decisions with respect to investments in securities
presenting an investment decision like that involved in the purchase of the
Securities, including investments in securities issued by the Company, and has
requested, received, reviewed and considered, either alone or with the
Purchaser's representative, all information the Purchaser deems relevant
(including the SEC Documents) in making an informed decision to purchase the
Securities.

                     (b) The Purchaser is acquiring the Securities being
acquired by the Purchaser pursuant to this Agreement for its own account for
investment only and with no present intention of distributing any of such
Securities or any arrangement or understanding with any other persons regarding
the distribution of such Securities, except in compliance with Section 5.1(c).

                                       5.
<PAGE>

                     (c) The Purchaser will not, directly or indirectly, offer,
sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy,
purchase or otherwise acquire or take a pledge of) any of the Securities
purchased hereunder except in compliance with the Securities Act, applicable
blue sky laws, and the rules and regulations promulgated thereunder.

                     (d) The Purchaser is an "accredited investor" within the
meaning of Rule 501 of Regulation D promulgated under the Securities Act or a
Qualified Institutional Buyer within the meaning of Rule 144A promulgated under
the Securities Act.

                     (e) The Purchaser has full right, power, authority and
capacity to enter into this Agreement and to consummate the transactions
contemplated hereby and has taken all necessary action to authorize the
execution, delivery and performance of this Agreement. Upon the execution and
delivery of this Agreement by the Purchaser, this Agreement shall constitute a
valid and binding obligation of the Purchaser, enforceable in accordance with
its terms, except (i) as limited by applicable bankruptcy, insolvency,
reorganization, moratorium or similar laws relating to or affecting the
enforcement of creditors' rights generally, (ii) as limited by equitable
principles generally, including any specific performance, and (iii) as to those
provisions of Section 9.7 relating to indemnity or contribution.

              5.2 The Purchaser represents and warrants to and covenants with
the Company that it has not engaged in any short sales of the Company's Common
Stock within the [...***...] period prior to the Closing Date and will not
engage in any short sales of the Company's Common Stock during the term of the
Collaboration Agreement.

              5.3 The Purchaser understands that nothing in the SEC Documents,
this Agreement or any other materials presented to the Purchaser in connection
with the purchase and sale of the Securities constitutes legal, tax or
investment advice and that independent legal counsel has reviewed these
documents and materials on the Purchaser's behalf. The Purchaser has consulted
such legal, tax and investment advisors as it, in its sole discretion, has
deemed necessary or appropriate in connection with its purchase of the
Securities.

       6. SURVIVAL OF REPRESENTATIONS, WARRANTIES AND AGREEMENTS, DISCLAIMER,
INDEMNIFICATION.

              6.1 SURVIVAL. Notwithstanding any investigation made by any party
to this Agreement, all covenants, agreements, representations and warranties
made by the Company and the Purchaser herein and in the certificates for the
securities delivered pursuant hereto shall survive the execution of this
Agreement, the delivery to the Purchaser of the Securities being purchased and
the payment therefore.

              6.2 DISCLAIMER. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT,
THE LICENSE AGREEMENT AND THE COLLABORATION AGREEMENT, NEITHER PARTY MAKES ANY
REPRESENTATION OR WARRANTY TO THE OTHER PARTY OF ANY NATURE, EXPRESS OR IMPLIED,
INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF NONINFRINGEMENT, MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE.

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                       6.
<PAGE>

              6.3 INDEMNIFICATION BY THE COMPANY. The Company agrees to
indemnify, defend and save harmless the Purchaser and its officers, directors,
agents employees, shareholders, legal representatives, successors and assigns
(the "PURCHASER INDEMNITEES"), and each of them, from and against any and all
liabilities, judgments, losses, damages, costs, charges, reasonable attorneys'
fees, and other expenses of every nature and character (collectively,
"LIABILITIES"), incurred by any Purchaser Indemnitee to the extent such
Liabilities arise out of or result from any material breach of the Company's
representations, warranties or covenants contained in this Agreement.

              6.4 INDEMNIFICATION BY THE PURCHASER. The Purchaser agrees to
indemnify, defend and save harmless the Company and its officers, directors,
agents, employees, shareholders, legal representatives, successors and assigns
(the "COMPANY INDEMNITEES"), and each of them, from any and all Liabilities
incurred by any Company Indemnitee to the extent such Liabilities arise out of
or result from any material breach of the Purchaser's representations,
warranties or covenants in this Agreement.

              6.5 LIMITATION OF LIABILITY. NEITHER PARTY SHALL BE ENTITLED TO
RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE
DAMAGES IN CONNECTION WITH THIS AGREEMENT.

       7. CONDITIONS TO COMPANY'S OBLIGATIONS AT CLOSING.

              7.1 CLOSING. The Company's obligation to sell, issue and deliver
the Shares to the Purchaser at the Closing shall be subject to the following
conditions to the extent not waived by the Company:

                     (a) RECEIPT OF PAYMENT. The Company shall have received
payment, by check or wire transfer of immediately available funds, in the full
amount of the Total Purchase Price.

                     (b) LICENSE AND COLLABORATION AGREEMENTS. The Company shall
have received a copy of the License Agreement and Collaboration Agreement
executed by the Purchaser.

                     (c) REPRESENTATIONS, WARRANTIES AND COVENANTS. The
representations and warranties made by the Purchaser in Section 5 hereof shall
be true and correct when made at the Closing and shall be true and correct on
the Closing Date. The Purchaser shall have performed and complied with all
obligations and conditions required to be performed and complied with by the
Purchaser under this Agreement on or prior to the Closing Date.

              7.2 MILESTONE CLOSING. The Company's obligation to sell, issue and
deliver the Milestone Shares to the Purchaser at the Milestone Closing shall be
subject to the condition that the Company shall have received payment, by check
or wire transfer of immediately available funds, in the full amount of the
Milestone Purchase Price.

                                       7.
<PAGE>

       8. CONDITIONS TO PURCHASERS' OBLIGATIONS AT CLOSING.

              8.1 CLOSING. The Purchaser's obligation to accept delivery of and
pay for the Shares at the Closing shall be subject to the following conditions
to the extent not waived by such Purchaser:

                     (a) ISSUANCE OF STOCK. The Purchaser shall have received
evidence of the issuance of a certificate representing the Shares in the name of
the Purchaser.

                     (b) REPRESENTATIONS, WARRANTIES AND COVENANTS. The
representations and warranties made by the Company in Section 4 hereof shall be
true and correct when made and shall be true and correct on the Closing Date.
The Company shall have performed and complied with all obligations and
conditions to be performed and complied with by the Company under this Agreement
on or prior to the Closing Date.

                     (c) LICENSE AND COLLABORATION AGREEMENTS. The Purchaser
shall have received a copy of the License Agreement and Collaboration Agreement
executed by the Company.

              8.2 MILESTONE CLOSING. The Purchaser's obligation to accept
delivery of and pay for the Milestone Shares at the Milestone Closing shall be
subject to the condition that the Purchaser shall have received evidence of the
issuance of a certificate representing the Milestone Shares in the name of the
Purchaser.

       9. RESTRICTIONS ON TRANSFER; REGISTRATION RIGHTS.

              9.1 CERTAIN DEFINITIONS. When used in this Section 9 of this
Agreement, the following terms shall have the following respective meanings:

                     (a) "FORM S-3" shall mean Form S-3 under the Securities Act
as in effect on the date of this Agreement, or any substantially similar,
equivalent or successor form under the Securities Act.

                     (b) "HOLDER" shall mean the Purchaser and each of its
permitted assigns under Section 9.2(c) then holding any Securities.

                     (c) "REGISTRATION EXPENSES" shall mean all expenses
incurred by the Company in complying with Sections 9.3 and 9.4 hereof,
including, without limitation, all registration, qualification and filing fees,
printing expenses, escrow fees, fees and disbursements of counsel to the
Company, blue sky fees and expenses, and the expense of any special audits
incident to or required by any such registration (but excluding the compensation
of regular employees of the Company which shall be paid in any event by the
Company).

                     (d) "SELLING EXPENSES" shall mean all underwriting
discounts and selling commissions and fees and disbursements of counsel
applicable to the applicable sale.

                     (e) "SPECIAL REGISTRATION STATEMENT" shall mean (i) a
registration statement relating to any employee benefit plan or (ii) a
registration statement relating to any

                                       8.
<PAGE>

corporate reorganization or transaction under Rule 145 of the Securities Act,
including any registration statements related to the resale of securities issued
in such a transaction or (iii) a registration statement related to stock issued
upon conversion of debt securities.

              9.2 RESTRICTIONS ON TRANSFER.

                     (a) The Purchaser agrees not to make any disposition of all
or any portion of the Securities unless and until:

                            (i) There is then in effect a registration statement
under the Securities Act covering such proposed disposition and such disposition
is made in accordance with such registration statement; or

                            (ii) (A) Except in connection with a sale exempt
from registration under Rule 144, the transferee has agreed in writing to be
bound by the terms of this Agreement, (B) the Purchaser shall have notified the
Company of the proposed disposition and shall have furnished the Company with a
detailed statement of the circumstances surrounding the proposed disposition,
and (C) if reasonably requested by the Company, the Purchaser shall have
furnished the Company with an opinion of counsel, reasonably satisfactory to the
Company, that such disposition will not require registration of such securities
under the Securities Act, provided that the Company will not require an opinion
of counsel for transactions pursuant to Rule 144 except in unusual
circumstances.

                            (iii) Notwithstanding the provisions of paragraphs
(a)(i) and (a)(ii) above, no such registration statement or opinion of counsel
shall be necessary for a transfer by the Purchaser (or its permitted transferee)
to the extent such transfer is made by (A) a partnership to its partners or
former partners in accordance with partnership interests, (B) a limited
liability company to its members or former members in accordance with their
interest in the limited liability company, or (C) a corporation to a subsidiary
of which it owns at least seventy-five percent (75%) of the capital stock or a
parent corporation that owns at least seventy-five percent (75%) of the capital
stock of the Purchaser.

                     (b) Each certificate representing Securities shall be
stamped or otherwise imprinted with a legend substantially similar to the
following (in addition to any legend required under applicable state securities
laws, as provided elsewhere in this Agreement or any other applicable agreement
or instrument):

              "THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
              ACT OF 1933, AS AMENDED. THEY MAY NOT BE OFFERED FOR SALE, PLEDGED
              OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
              STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR UNLESS THE
              COMPANY HAS RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO THE
              COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED."

                                       9.
<PAGE>

       The Company shall be obligated to reissue promptly unlegended
certificates at the request of the Purchaser if the Purchaser shall have
obtained an opinion of counsel (which counsel may be counsel to the Company)
reasonably acceptable to the Company to the effect that the securities proposed
to be disposed of may lawfully be so disposed of (with no need for compliance
with Rule 144) without registration, qualification or legend.

       Any legend endorsed on an instrument pursuant to applicable state
securities laws and the stop-transfer instructions with respect to such
securities shall be removed upon receipt by the Company of an order of the
appropriate blue sky authority authorizing such removal.

                     (c) The registration rights granted under Section 9.3 of
this Agreement shall not be transferable except in connection with transfers
permitted under Section 9.2 (iii).

              9.3 REGISTRATION PROCEDURES. The Company is obligated to do the
following:

                     (a) No later than (i) [...***...] of the Closing Date, with
respect to the Shares, and (ii) [...***...] following the Milestone Closing
Date, with respect to the Milestone Shares, the Company shall prepare and file
with the SEC one or more registration statements in order to register with the
SEC the resale by the Holders, from time to time, of the Shares or the Milestone
Shares, as applicable, through Nasdaq or the facilities of any national
securities exchange on which the Company's Common Stock is then traded, or in
privately negotiated transactions (a "REGISTRATION STATEMENT"); provided,
however, that, if the Company has filed a registration statement within
[...***...] of the proposed date of filing of the applicable Registration
Statement, the Company shall not be obligated to file a Registration Statement
until after the end of such [...***...] period. The Company shall use its best
efforts to cause each such Registration Statement to be declared effective as
soon thereafter as reasonably possible. The Company shall promptly notify the
Holders of the effectiveness of each such Registration Statement.

                     (b) The Company shall prepare and file with the SEC (i)
such amendments and supplements to the Registration Statement and the prospectus
used in connection therewith, (ii) such SEC Documents and (iii) such other
filings required by the SEC, in each case as may be necessary to keep the
Registration Statement continuously effective and not misleading until the
earliest of (A) such date as all of the Securities held by the Holders that are
registered under such Registration Statement have been resold, or (B) such time
as all of the Securities held by the Holders that are registered under such
Registration Statement can be sold within a given [...***...] period pursuant to
Rule 144 under the Securities Act. Notwithstanding the foregoing, if, at any
time following the effectiveness of a Registration Statement, the Company shall
have determined that the Company may be required to disclose any material
corporate development, the Company may suspend the effectiveness of a
Registration Statement until such time as an amendment to such Registration
Statement has been filed by the Company and declared effective by the SEC or
until such time as the Company has filed an appropriate report with the SEC
pursuant to the Exchange Act, which suspension shall endure for such period as
deemed necessary by the Company upon advice of counsel (a "SUSPENSION PERIOD"),
by giving notice to the Holders. The Company will use commercially reasonable
efforts to limit the length of any Suspension Period to a reasonable period of
time (anticipated to be no more then [...***...] except to the extent a longer
period is required due to extenuating

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                      10.
<PAGE>

circumstances), and further, the Company will use reasonable efforts to amend or
supplement such prospectus in order to cause such prospectus not to include any
untrue statement of a material fact or omit to state a material fact required to
be stated therein or necessary to make the statements therein not misleading in
the light of the circumstances then existing and end the Suspension Period. Each
Holder will provide the Company written notice of its intention to sell any
Securities that are registered under a Registration Statement pursuant to such
Registration Statement at least [...***...] prior to such proposed sale, but
will not effect such sale if it receives written notice from the Company that a
Suspension Period is then in effect prior to the date of such proposed sale.
Each Holder agrees that, upon receipt of any notice from the Company of a
Suspension Period, the Holder will not sell any Securities pursuant to the
Registration Statement until (i) the Holder is advised in writing by the Company
that the use of the applicable prospectus may be resumed, (ii) the Holder has
received copies of any additional or supplemental or amended prospectus, if
applicable, and (iii) the Holder has received copies of any additional or
supplemental filings which are incorporated or deemed to be incorporated by
reference in such prospectus.

                     (c) In order to facilitate the public sale or other
disposition of all or any of the Securities by the Holders, the Company shall
furnish to the Holders with respect to the Securities registered under a
Registration Statement such number of copies of prospectuses, prospectus
supplements and preliminary prospectuses as the Holders reasonably request in
conformity with the requirements of the Securities Act.

                     (d) The Company shall file any documents required of the
Company for normal blue sky clearance in states specified in writing by the
Holders; provided, however, that the Company shall not be required to qualify to
do business or consent to service of process in any jurisdiction in which it is
not now so qualified or has not so consented.

              9.4 EXPENSES OF REGISTRATION. Except as specifically provided
herein, all Registration Expenses incurred in connection with any registration
under Section 9.3 herein shall be borne by the Company. All Selling Expenses
incurred in connection with any registrations hereunder, shall be borne by the
Holders.

              9.5 TERMINATION OF REGISTRATION RIGHTS. All registration rights
granted to the Holders under this Section 9 shall terminate and be of no further
force and effect upon the date that all Registrable Securities held by the
Holders may be sold under Rule 144 during any [...***...] period.

              9.6 FURNISHING INFORMATION. It shall be a condition precedent to
the obligations of the Company to take any action pursuant to Section 9.3 that
each Holder shall furnish to the Company such information regarding itself, the
Securities held by the Holder and the intended method of disposition of such
securities as shall be required to effect the registration of the Securities.

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                      11.
<PAGE>

              9.7 INDEMNIFICATION. In the event any Securities are included in a
Registration Statement under Section 9.3:

                     (a) To the extent permitted by law, the Company will
indemnify and hold harmless the Holders, the partners, officers, directors and
legal counsel of the Holders, any underwriter (as defined in the Securities Act)
for the Holders and each person, if any, who controls the Holder or underwriter
within the meaning of the Securities Act or the Exchange Act, against any
losses, claims, damages, expenses (including attorney fees) or liabilities
(joint or several) to which they may become subject under the Securities Act,
the Exchange Act or other federal or state law, insofar as such losses, claims,
damages or liabilities (or actions in respect thereof) arise out of or are based
upon any of the following statements, omissions or violations (collectively a
"VIOLATION") by the Company: (i) any untrue statement or alleged untrue
statement of a material fact contained in such Registration Statement, including
any preliminary prospectus or final prospectus contained therein or any
amendments or supplements thereto; (ii) the omission or alleged omission to
state therein a material fact required to be stated therein, or necessary to
make the statements therein not misleading; or (iii) any violation or alleged
violation by the Company of the Securities Act, the Exchange Act, any state
securities law or any rule or regulation promulgated under the Securities Act,
the Exchange Act or any state securities law in connection with the offering
covered by such Registration Statement; and the Company will reimburse the
Holders and each such partner, officer or director, underwriter or controlling
person for any legal or other expenses reasonably incurred by them in connection
with investigating or defending any such loss, claim, damage, liability or
action; provided however, that the indemnity agreement contained in this Section
9.7(a) shall not apply to amounts paid in settlement of any such loss, claim,
damage, liability or action if such settlement is effected without the consent
of the Company, which consent shall not be unreasonably withheld, nor shall the
Company be liable in any such case for any such loss, claim, damage, liability
or action to the extent that it arises out of or is based upon a Violation which
occurs in reliance upon and in conformity with written information furnished
expressly for use in connection with such registration by the Holders or any
such partner, officer, director, underwriter or controlling person of the
Holders.

                     (b) To the extent permitted by law, the Holders will, if
Securities held by the Holders are included in the securities as to which such
registration, qualifications or compliance is being effected, indemnify and hold
harmless the Company, each of its directors, its officers and legal counsel and
each person, if any, who controls the Company within the meaning of the
Securities Act, any underwriter and any other Holder selling securities under
such Registration Statement or any of such other Holder's partners, directors or
officers or any person who controls the Holder, against any losses, claims,
damages, expenses (including attorney fees), or liabilities (joint or several)
to which the Company or any such director, officer, counsel, controlling person,
underwriter or other such Holder, or partner, director, officer or controlling
person of such other Holder may become subject under the Securities Act, the
Exchange Act or other federal or state law, insofar as such losses, claims,
damages or liabilities (or actions in respect thereto) arise out of or are based
upon any Violation, in each case to the extent (and only to the extent) that
such Violation occurs in reliance upon and in conformity with written
information furnished by the Holders under an instrument duly executed by the
Holders and stated to be specifically for use in connection with such
registration; and the Holders will reimburse any legal or other expenses
reasonably incurred by the Company or any such director,

                                      12.
<PAGE>

officer, counsel, controlling person, underwriter or other Holder, or partner,
officer, director or controlling person of such other Holder in connection with
investigating or defending any such loss, claim, damage, liability or action if
it is judicially determined that there was such a Violation; provided, however,
that the indemnity agreement contained in this Section 9.7(b) shall not apply to
amounts paid in settlement of any such loss, claim, damage, liability or action
if such settlement is effected without the consent of the Holder, which consent
shall not be unreasonably withheld; provided further, that in no event shall any
indemnity under this Section 9.7(b) exceed the proceeds from the offering
received by the Holder.

                     (c) Promptly after receipt by an indemnified party under
this Section 9.7 of notice of the commencement of any action (including any
governmental action), such indemnified party will, if a claim in respect thereof
is to be made against any indemnifying party under this Section 9.7, deliver to
the indemnifying party a written notice of the commencement thereof and the
indemnifying party shall have the right to participate in, and, to the extent
the indemnifying party so desires, jointly with any other indemnifying party
similarly noticed, to assume the defense thereof with counsel mutually
satisfactory to the parties; provided, however, that an indemnified party shall
have the right to retain its own counsel, with the fees and expenses to be paid
by the indemnifying party, if representation of such indemnified party by the
counsel retained by the indemnifying party would be inappropriate due to actual
or potential differing interests between such indemnified party and any other
party represented by such counsel in such proceeding. The failure to deliver
written notice to the indemnifying party within a reasonable time of the
commencement of any such action, if materially prejudicial to its ability to
defend such action, shall relieve such indemnifying party of any liability to
the indemnified party under this Section 9.7, but the omission so to deliver
written notice to the indemnifying party will not relieve it of any liability
that it may have to any indemnified party otherwise than under this Section 9.7.

                     (d) If the indemnification provided for in this Section 9.7
is held by a court of competent jurisdiction to be unavailable to an indemnified
party with respect to any losses, claims, damages or liabilities referred to
herein, the indemnifying party, in lieu of indemnifying such indemnified party
thereunder, shall to the extent permitted by applicable law contribute to the
amount paid or payable by such indemnified party as a result of such loss,
claim, damage or liability in such proportion as is appropriate to reflect the
relative fault of the indemnifying party on the one hand and of the indemnified
party on the other in connection with the Violation(s) that resulted in such
loss, claim, damage or liability, as well as any other relevant equitable
considerations. The relative fault of the indemnifying party and of the
indemnified party shall be determined by a court of law by reference to, among
other things, whether the untrue or alleged untrue statement of a material fact
or the omission to state a material fact relates to information supplied by the
indemnifying party or by the indemnified party and the parties' relative intent,
knowledge, access to information and opportunity to correct or prevent such
statement or omission; provided, that in no event shall any contribution by the
Purchaser hereunder exceed the proceeds from the offering received by the
Holders.

                     (e) The obligations of the Company and the Holders under
this Section 9.7 shall survive completion of any offering of Registrable
Securities in a Registration Statement. No indemnifying party, in the defense of
any such claim or litigation, shall, except with the consent of each indemnified
party, consent to entry of any judgment or enter into any

                                      13.
<PAGE>

settlement which does not include as an unconditional term thereof the giving by
the claimant or plaintiff to such indemnified party of a release from all
liability in respect to such claim or litigation.

              9.8 "MARKET STAND-OFF" AGREEMENT. If requested by the
representative of the underwriters of Common Stock (or other securities) of the
Company, the Holders shall not sell or otherwise transfer or dispose of any
Common Stock (or other securities) of the Company held by the Holders (other
than those included by the Holders in the registration) for a period specified
by the representative of the underwriters, in any case not to exceed one hundred
eighty (180) days following any registered offering of the Common Stock of the
Company.

       The obligations described in this Section 9.8 shall not apply to a
registration effected pursuant to a Special Registration Statement. The Company
may impose stop-transfer instructions with respect to the shares of Common Stock
(or other securities) subject to the foregoing restriction until the end of said
periods.

       10. RIGHT OF FIRST REFUSAL.

              10.1 SUBSEQUENT OFFERINGS. The Purchaser shall have a right of
first refusal to purchase its pro rata share of all Equity Securities (as
defined below), that the Company may, from time to time, propose to sell and
issue after the date of this Agreement, other than the Equity Securities
excluded by Section 10.6 hereof. The Purchaser's pro rata share is equal to the
ratio of (a) the number of shares of Common Stock purchased pursuant to this
Agreement, then held by the Purchaser or any transferee pursuant to Section
9.2(a)(iii), to (b) the total number of shares of the Company's outstanding
Common Stock (including all shares of Common Stock issued or issuable upon the
conversion of any Equity Securities or upon exercise of any outstanding warrants
or options) immediately prior to the issuance of the Equity Securities. The term
"EQUITY SECURITIES" shall mean (i) any Common Stock, Preferred Stock or other
security of the Company, (ii) any security convertible, with or without
consideration, into any Common Stock, Preferred Stock or other security
(including any option, warrant or other right to purchase such a convertible
security), (iii) any security carrying any option, warrant or right to subscribe
to or purchase any Common Stock, Preferred Stock or other security, or (iv) any
such option, warrant or right.

              10.2 EXERCISE OF RIGHT OF FIRST REFUSAL. If the Company proposes
to issue any Equity Securities in a transaction subject to Section 10.1, it
shall give the Purchaser written notice of its intention, describing the Equity
Securities, the price and the terms and conditions upon which the Company
proposes to issue the same (an "OFFERING NOTICE"). The Purchaser shall have
[...***...] from the giving of such Offering Notice to agree to purchase its pro
rata share of the Equity Securities for the price and upon the terms and
conditions specified in the notice by giving written notice to the Company and
stating therein the quantity of Equity Securities to be purchased.
Notwithstanding the foregoing, the Company shall not be required to offer or
sell such Equity Securities to the Purchaser if doing so would cause the Company
to be in violation of applicable federal securities laws by virtue of such offer
or sale; provided, however, the Company agrees to use its reasonable best
efforts to take whatever action may be necessary or appropriate to comply with
applicable federal securities laws in connection with such offer or sale.
Notwithstanding anything herein to the contrary, such action by the Company

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                      14.
<PAGE>

shall include, but not be limited to, providing the Purchaser with any
additional information provided to the prospective investors in the applicable
transaction so long as the Purchaser has executed an agreement not to disclose
such information in a form and substance as reasonably requested by the Company.

              10.3 ISSUANCE OF EQUITY SECURITIES TO OTHER PERSONS. If the
Purchaser fails to exercise in full the right of first refusal, the Company
shall have [...***...] thereafter to sell the Equity Securities in respect of
which the Purchaser's right was not exercised, at a price and upon general terms
and conditions no more favorable to the purchasers thereof in any material
respect than specified in the Company's Offering Notice to the Purchaser. If the
Company has not sold such Equity Securities within [...***...] of the Offering
Notice, the Company shall not thereafter issue or sell any Equity Securities,
without first offering such securities to the Purchaser in the manner provided
in this Section 10.

              10.4 TERMINATION OF RIGHT OF FIRST REFUSAL. The right of first
refusal established by this Section 10 shall terminate on the termination of the
Collaboration Agreement.

              10.5 NO TRANSFER OF RIGHT OF FIRST REFUSAL. The right of first
refusal established by this Section 10 may not be assigned or transferred,
except as otherwise provided in Section 9.2(a)(iii).

              10.6 EXCLUDED SECURITIES. The right of first refusal established
by Section 10.1 shall have no application to any of the following Equity
Securities:

                     (a) shares of Common Stock (and/or options, warrants or
other Common Stock purchase rights issued pursuant to such options, warrants or
other rights) issued or to be issued to employees, officers or directors of, or
consultants or advisors to the Company or any subsidiary, pursuant to stock
purchase or stock option plans or other compensatory arrangements that are
approved by the Board of Directors;

                     (b) any Equity Securities issued pursuant to any rights,
agreements, options or warrants outstanding as of the date of this Agreement,
and stock issued pursuant to any rights, agreements, options or warrants
exercised after the date of this Agreement;

                     (c) any Equity Securities issued in connection with an
underwritten public offering;

                     (d) any Equity Securities issued for consideration other
than cash pursuant to a merger, consolidation, acquisition or similar business
combination whereby the stockholders of the Company will own more than fifty
percent (50%) of the voting power of the combined entity;

                     (e) any Equity Securities issued in connection with any
stock split, stock dividend or recapitalization by the Company;

                     (f) shares of Common Stock issued upon conversion of any
Equity Securities;

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                      15.
<PAGE>

                     (g) shares of Common Stock issued pursuant to this
Agreement;

                     (h) any Equity Securities issued pursuant to any equipment
leasing or other credit finance arrangement entered into by the Company in the
ordinary course of business; and

                     (i) any Equity Securities issued in connection with
strategic transactions involving the Company and any third party, including (i)
joint ventures, manufacturing, marketing, corporate partnering or distribution
arrangements, or (ii) technology transfer, collaboration, research or
development arrangements; provided that such strategic transactions and the
issuance of Equity Securities therein, has been approved by the Company's Board
of Directors.

              10.7 CONDITION TO THE PURCHASER'S RIGHT OF FIRST REFUSAL.
Notwithstanding any other provisions in this Agreement, the Purchaser shall not
be entitled to exercise the right of first refusal contained in this Section
10.1 if such Purchaser or Holder has entered into any Restricted Transaction (as
defined below) between the date of any Offering Notice and the closing of the
transaction described in such Offering Notice.

       11. ADDITIONAL COVENANTS.

              11.1 RESTRICTED TRANSACTIONS. For the term of the Collaboration
Agreement, the Purchaser shall not, and shall not authorize, instruct,
facilitate or permit any of its affiliates or any other person or entity, to
engage in any of the following (a "RESTRICTED TRANSACTION"): (a) offer, sell or
contract to sell securities of the Company or any of its affiliates or
successors or any instruments convertible into or exchangeable or exercisable
for securities of the Company or any of its affiliates or successors (the
"COMPANY SECURITIES") in a private placement or similar transaction, except as
permitted by Section 9.2(a)(iii), (b) sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant for
the sale of the Company Securities, or (c) enter into any swap or any other
agreement or any transaction that transfers, in whole or in part directly or
indirectly, the economic consequence of ownership of the Company Securities,
whether any such swap or transaction is to be settled by delivery of common
stock or other securities, in cash or otherwise.

              11.2 STANDSTILL. The Purchaser agrees that for the term of the
Collaboration Agreement, except with the prior written consent of the Company,
the Purchaser shall not, and shall not permit any of its officers, directors or
affiliates to:

                     (a) acquire, offer to acquire, agree to acquire or cause or
effect the acquisition of, directly or indirectly, by purchase or otherwise,
beneficial ownership of any securities or instruments convertible into any of
the Company Securities such that the aggregate beneficial ownership of the
Purchaser, its officers, directors and affiliates (on a combined basis) exceeds
[...***...] of the Company's outstanding Common Stock on a fully-diluted basis
(including all shares of Common Stock issued or issuable upon the conversion or
exercise of any Equity Securities).

                     (b) solicit or encourage any other entity to encourage or
solicit proxies (as such terms are defined in Regulation 14A under the Exchange
Act) with respect to any matter

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                      16.
<PAGE>

involving the Company or otherwise initiate, propose or solicit, or induce any
other person or entity to initiate, propose or solicit any stockholder of the
Company, any stockholder proposal, any tender offer for Company Securities, any
change of control of the Company, or for the purpose of convening a
stockholders' meeting of the Company;

                     (c) deposit any Company Securities in any voting trust or
subject them to any voting agreement or other agreement of similar effect;

                     (d) join or form any partnership, limited partnership,
syndicate, or other group within the meaning of Section 13(d)(3) of the Exchange
Act for the purpose of acquiring, holding or disposing of beneficial ownership
of any Company Securities or encourage, advise or, for the purpose of
circumventing or avoiding any of the provisions of this Agreement, assist any
person or entity to do any of the foregoing or otherwise take any action
individually or jointly with any partnership, limited partnership, syndicate, or
other group or assist any other person, corporation, entity or group in taking
any action it could not individually take under this Agreement;

                     (e) make, effect, cause, initiate or participate in any
Acquisition Transaction (as defined below) with respect to the Company; or

                     (f) make any public proposals to the Company or any of its
affiliates, directors, officers, employees, agents, representatives, successors
or security holders concerning any Acquisition Transaction relating to the
Company or any affiliate or successor of the Company or take any action that
would require the Company to make a public announcement regarding the
possibility of an Acquisition Transaction with the Purchaser or any of its
affiliates.

                     (g) For purposes of this Section 11.2, "ACQUISITION
TRANSACTION" shall mean any transaction involving: (i) any sale, license, lease,
exchange, transfer or other disposition of the assets of the Company or any
subsidiary of the Company constituting more than fifty percent (50%) of the
consolidated assets of the Company or accounting for more than fifty percent
(50%) of the consolidated revenues of the Company in any one transaction or in a
series of related transactions; (ii) any offer to purchase, tender offer,
exchange offer or any similar transaction or series of related transactions made
by any person involving more than fifty percent (50%) of the outstanding shares
of capital stock of the Company; or (iii) any merger, consolidation, business
combination, share exchange, reorganization or similar transaction or series of
related transactions involving the Company or any subsidiary of the Company
whereby the holders of voting capital stock of the Company immediately prior to
any such transaction hold less than fifty percent (50%) of the voting capital
stock of the Company or the surviving corporation immediately after the
consummation of any such transaction.

       12. BROKER'S FEE. The Company and the Purchaser hereby represent that,
there are no brokers or finders entitled to compensation in connection with the
sale of the Securities, and shall indemnify each other for any such fees for
which they are responsible.

       13. NOTICES. All notices, requests, consents and other communications
hereunder shall be in writing, shall be sent by confirmed facsimile or mailed by
first-class registered or certified airmail, or nationally recognized overnight
express courier, postage prepaid, and shall

                                      17.
<PAGE>

be deemed given when so sent in the case of facsimile transmission, or when so
received in the case of mail or courier, and addressed as follows:

                    (a)       if to the Company, to:

                              Epimmune Inc.
                              5820 Nancy Ridge Drive, Suite 100
                              San Diego, CA  92121
                              Attention:  President and Chief Executive Officer
                              Fax No.:  858-860-2600

                    with a copy to:

                              Cooley Godward LLP
                              4365 Executive Drive, Suite 1100
                              San Diego, CA  92121
                              Attention:  L. Kay Chandler, Esq.
                              Fax No.:  858-453-3555

or to such other person at such other place as the Company shall designate to
the Purchaser in writing; and

                    (b)       if to the Purchaser, to:

                              Genencor International, Inc.
                              925 Page Mill Road
                              Palo Alto, CA 94304
                              Attention: General Counsel
                              Fax No.:  650-845-6507

or to such other person at such other place as the Purchaser shall designate to
the Company in writing.

       14. MISCELLANEOUS.

              14.1 WAIVERS AND AMENDMENTS. Neither this Agreement nor any
provision hereof may be changed, waived, discharged, terminated, modified or
amended except upon the written consent of the Company and the Purchaser.

              14.2 HEADINGS. The headings of the various sections of this
Agreement have been inserted for convenience of reference only and shall not be
deemed to be part of this Agreement.

              14.3 SEVERABILITY. In case any provision contained in this
Agreement should be invalid, illegal or unenforceable in any respect, the
validity, legality and enforceability of the remaining provisions contained
herein shall not in any way be affected or impaired thereby.

                                      18.
<PAGE>

              14.4 GOVERNING LAW. This Agreement shall be governed by and
construed in accordance with the laws of the State of California, without regard
to conflicts of law principles.

              14.5 COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall constitute an original, but all of which, when
taken together, shall constitute but one instrument, and shall become effective
when one or more counterparts have been signed by each party hereto and
delivered to the other parties.

              14.6 SUCCESSORS AND ASSIGNS. Except as otherwise expressly
provided herein, the provisions hereof shall inure to the benefit of, and be
binding upon, the successors, assigns, heirs, executors and administrators of
the parties hereto.

              14.7 ENTIRE AGREEMENT. This Agreement and other documents
delivered pursuant hereto, including the exhibits, constitute the full and
entire understanding and agreement between the parties with regard to the
subjects hereof and thereof.

              14.8 PAYMENT OF FEES AND EXPENSES. Each of the Company and the
Purchaser shall bear its own expenses and legal fees incurred on its behalf with
respect to this Agreement and the transactions contemplated hereby. If any
action at law or in equity is necessary to enforce or interpret the terms of
this Agreement, the prevailing party shall be entitled to reasonable attorney's
fees, costs and necessary disbursements in addition to any other relief to which
such party may be entitled.

                           [SIGNATURE PAGE TO FOLLOW]

                                      19.
<PAGE>

       IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed by their duly authorized representatives as of the day and year first
above written.

                                        EPIMMUNE INC.

                                        By: /s/ Robert J. De Vaere
                                            ------------------------------------
                                            Robert J. De Vaere
                                            Vice President, Finance and
                                            Chief Financial Officer

                                        GENENCOR INTERNATIONAL, INC.

                                        By: /s/ Debby Jo Blank
                                            ------------------------------------

                                        Name: Debby Jo Blank
                                              ----------------------------------

                                        Title:
                                               ---------------------------------

                SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT

<PAGE>

                                    EXHIBIT A

                             SCHEDULE OF EXCEPTIONS

[...***...]

                                               *CONFIDENTIAL TREATMENT REQUESTED

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}]]